These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 32862147)

  • 1. Impact of P-Glycoprotein-Mediated Active Efflux on Drug Distribution into Lumbar Cerebrospinal Fluid in Nonhuman Primates.
    Nagaya Y; Katayama K; Kusuhara H; Nozaki Y
    Drug Metab Dispos; 2020 Nov; 48(11):1183-1190. PubMed ID: 32862147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of utility of cerebrospinal fluid drug concentration as a surrogate for interstitial fluid concentration using microdialysis coupled with cisternal cerebrospinal fluid sampling in wild-type and Mdr1a(-/-) rats.
    Nagaya Y; Nozaki Y; Takenaka O; Watari R; Kusano K; Yoshimura T; Kusuhara H
    Drug Metab Pharmacokinet; 2016 Feb; 31(1):57-66. PubMed ID: 26830080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of cerebrospinal fluid drug concentration as a surrogate for unbound brain concentration in nonhuman primates.
    Nagaya Y; Nozaki Y; Kobayashi K; Takenaka O; Nakatani Y; Kusano K; Yoshimura T; Kusuhara H
    Drug Metab Pharmacokinet; 2014; 29(5):419-26. PubMed ID: 24806821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse.
    Kido Y; Nanchi I; Fusamae Y; Matsuzaki T; Akazawa T; Sawada H; Iwasaki M; Nishida K; Tsuchiya E; Okuda T
    Drug Metab Pharmacokinet; 2022 Feb; 42():100426. PubMed ID: 34974334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Practical Perspective on the Evaluation of Small Molecule CNS Penetration in Drug Discovery.
    Huang L; Wells MC; Zhao Z
    Drug Metab Lett; 2019; 13(2):78-94. PubMed ID: 30854983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.
    Feng B; Doran AC; Di L; West MA; Osgood SM; Mancuso JY; Shaffer CL; Tremaine L; Liras J
    J Pharm Sci; 2018 Aug; 107(8):2225-2235. PubMed ID: 29608887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational CNS Steady-State Drug Disposition Model in Rats, Monkeys, and Humans for Quantitative Prediction of Brain-to-Plasma and Cerebrospinal Fluid-to-Plasma Unbound Concentration Ratios.
    Sato S; Matsumiya K; Tohyama K; Kosugi Y
    AAPS J; 2021 Jun; 23(4):81. PubMed ID: 34085128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures.
    Venkatakrishnan K; Tseng E; Nelson FR; Rollema H; French JL; Kaplan IV; Horner WE; Gibbs MA
    Drug Metab Dispos; 2007 Aug; 35(8):1341-9. PubMed ID: 17470526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates.
    Braun C; Sakamoto A; Fuchs H; Ishiguro N; Suzuki S; Cui Y; Klinder K; Watanabe M; Terasaki T; Sauer A
    Mol Pharm; 2017 Oct; 14(10):3436-3447. PubMed ID: 28880093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of the unbound brain concentration of P-glycoprotein substrates or nonsubstrates by a serial cerebrospinal fluid sampling technique in rats.
    Mariappan TT; Kurawattimath V; Gautam SS; Kulkarni CP; Kallem R; Taskar KS; Marathe PH; Mandlekar S
    Mol Pharm; 2014 Feb; 11(2):477-85. PubMed ID: 24380373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid.
    Westerhout J; Smeets J; Danhof M; de Lange EC
    J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):327-42. PubMed ID: 23539188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid.
    Kaddoumi A; Choi SU; Kinman L; Whittington D; Tsai CC; Ho RJ; Anderson BD; Unadkat JD
    Drug Metab Dispos; 2007 Sep; 35(9):1459-62. PubMed ID: 17591677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
    Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
    Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful Prediction of Human Steady-State Unbound Brain-to-Plasma Concentration Ratio of P-gp Substrates Using the Proteomics-Informed Relative Expression Factor Approach.
    Storelli F; Anoshchenko O; Unadkat JD
    Clin Pharmacol Ther; 2021 Aug; 110(2):432-442. PubMed ID: 33675056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening novel CNS drug candidates for P-glycoprotein interactions using the cell line iP-gp: In vitro efflux ratios from iP-gp and MDCK-MDR1 monolayers compared to brain distribution data from mice.
    Ozgür B; Saaby L; Janfelt C; Langthaler K; Eneberg E; Jacobsen AM; Badolo L; Montanari D; Brodin B
    Eur J Pharm Biopharm; 2021 Dec; 169():211-219. PubMed ID: 34756975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
    Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
    Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calculation of an Apical Efflux Ratio from P-Glycoprotein (P-gp) In Vitro Transport Experiments Shows an Improved Correlation with In Vivo Cerebrospinal Fluid Measurements in Rats: Impact on P-gp Screening and Compound Optimization.
    Fischer H; Senn C; Ullah M; Cantrill C; Schuler F; Yu L
    J Pharmacol Exp Ther; 2021 Mar; 376(3):322-329. PubMed ID: 33288523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys.
    Uchida Y; Wakayama K; Ohtsuki S; Chiba M; Ohe T; Ishii Y; Terasaki T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):578-88. PubMed ID: 24947467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model.
    Peng J; Ladumor MK; Unadkat JD
    Drug Metab Dispos; 2022 May; 50(5):613-623. PubMed ID: 35149540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.